Cipla Limited (NSEI:CIPLA) is eyeing acquisitions and inorganic partnerships in the US market while consolidating its presence across segments in the domestic market. The Mumbai-based company is also looking to improve the top line in Europe and margin expansion in South Africa. "Product launches through delisting strategy and as well as inorganic partnerships and acquisitions will remain one of our key priorities for the US market," Cipla Global Chief Financial Officer Ashish Adukia said in an analyst call.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,494 INR | +0.95% | +3.55% | +19.84% |
May. 27 | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
May. 23 | Nomura Adjusts Cipla’s Price Target to INR1,535 From INR1,486, Keeps at Neutral | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.84% | 14.36B | |
+17.43% | 42.25B | |
+15.37% | 21.27B | |
+16.67% | 15.23B | |
+51.59% | 12.74B | |
-0.05% | 6.79B | |
-12.40% | 6.61B | |
-8.87% | 5.73B | |
+14.28% | 5.66B | |
+6.11% | 4.8B |
- Stock Market
- Equities
- CIPLA Stock
- News Cipla Limited
- Cipla Eyes Acquisitions and Inorganic Partnerships in the US, European markets